Critical Limb Ischemia Treatment Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
The global critical limb ischemia treatment market was estimated to be US$ 4.57 Billion in 2022 and is expected grow at a CAGR of 7.8% between 2023 to 2032.
Critical Limb Ischemia (CLI) is a severe form of peripheral arterial disease (PAD) in which there is a blockage or narrowing of the arteries that supply blood to the legs and feet. This leads to a reduction in blood flow and oxygen supply to the lower limbs, which can cause pain, wounds, and ulcers that are slow to heal or do not heal at all.
CLI is considered a medical emergency as it increases the risk of amputation and can lead to serious complications, including gangrene and sepsis. The primary cause of CLI is the accumulation of plaque in the arteries, which can be due to various factors, such as smoking, high blood pressure, high cholesterol, and diabetes.
Major drivers for growth:
Rising the incidence of PAD and CLI is boosting the market growth
Critical limb ischemia (CLI) is a medical condition that affects the blood flow to the legs and feet and is caused by peripheral artery disease (PAD).
The critical limb ischemia treatment market is driven by several factors, including the increasing incidence of PAD and CLI, the rising geriatric population, growing awareness of CLI and available treatments, technological advancements in diagnostic and therapeutic devices, rising adoption of minimally invasive procedures, growth in healthcare spending and infrastructure development, and the growing prevalence of lifestyle diseases such as diabetes and obesity.
Advances in diagnostic and therapeutic devices, such as drug-eluting stents and drug-coated balloons, have improved the accuracy and efficacy of CLI treatments and are driving the market growth. Minimally invasive procedures, such as angioplasty and stenting, are becoming more popular due to their advantages over traditional surgical treatments, such as a shorter recovery time and lower risk of complications.
The increasing spending on healthcare and the development of healthcare infrastructure in developing countries is also expected to drive market growth. The growing prevalence of lifestyle diseases is a major risk factor for CLI and is expected to drive the demand for CLI treatments. Overall, the critical limb ischemia treatment market is expected to grow as more people seek treatment for this condition.
Treatment type segmentation of Global Critical Limb Ischemia Treatment Market
Medication segment is the fastest-growing in the market
On the basis of a treatment, the market is segmented into two major categories Medication, and Surgery. Among these, currently the surgical segment is the largest segment of the market, accounting for the majority of critical limb ischemia treatments. This is due to the fact that in many cases, CLI requires surgical intervention to restore blood flow to the affected limb, particularly in cases of advanced disease or tissue loss.
While, the fastest-growing segment of the market is the medication segment, which includes angiogenesis drugs, anti-platelet drugs, and others. This is largely due to the development of new medications that offer improved efficacy and fewer side effects compared to traditional treatments, as well as an increasing focus on minimally invasive treatments for CLI.
The surgery segment is further segmented into Embolic Protection Devices, and Peripheral Dilatation System.
Additionally, the increasing demand for minimally invasive treatments that can provide improved patient outcomes with reduced risk of complications is driving growth in the medication segment. The growing adoption of these treatments is expected to continue driving growth in the medication segment in the coming years, making it one of the fastest-growing segments of the critical limb ischemia treatment market.
Medication segment is further segmented into Antihypertensive Agents, Antiplatelet Drugs, Antithrombotic Agents, Lipid-lowering Agents, and Other drugs.
End-user segmentation of Global Critical Limb Ischemia Treatment Market
Ambulatory surgical center is the fastest-growing end-user due to its convenience and accessibility
On the basis of end-users, the market is segmented into Hospitals, Clinics, and Ambulatory surgical centers. The largest segment of the market is hospitals, accounting for a significant share of the total critical limb ischemia treatments. This is due to the presence of well-equipped facilities, a large patient base, and the availability of specialized services and personnel, such as vascular surgeons and interventional radiologists.
While, the fastest-growing segment of the market is ambulatory surgical centers, which offer patients a more convenient and cost-effective alternative to hospital-based procedures. These centers specialize in minimally invasive surgical procedures and are equipped with the latest diagnostic and therapeutic devices, offering patients improved outcomes and reduced recovery times compared to traditional hospital-based treatments.
Another factor driving growth in the ambulatory surgical center segment is the increasing demand for outpatient surgical procedures, which allow patients to return home on the same day as their procedure, reducing the cost and time associated with hospital stays.
Regional trends of the Global Critical Limb Ischemia Treatment Market
Availability of new and advanced medication is driving the growth of the Asia-Pacific CLI treatments market
Geographically, the global critical limb ischemia treatment market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. Currently, the North American region is the largest segment of the market, accounting for a significant share of the global market.
This is due to factors such as the presence of a large number of leading healthcare companies, a well-established healthcare infrastructure, and a high awareness of critical limb ischemia and available treatments.
Additionally, the presence of a large number of patients with critical limb ischemia and a high incidence of lifestyle diseases, such as diabetes, is driving the demand for CLI treatments in North America.
The fastest-growing segment of the global critical limb ischemia treatment market is the Asia-Pacific region, particularly in countries such as China, India, and Japan. This is due to the increasing incidence of critical limb ischemia, rising geriatric population, growing awareness of CLI and available treatments, and the development of healthcare infrastructure in the region.
The increasing adoption of minimally invasive treatments and the availability of new and advanced medications and devices are also driving the growth of the market in the Asia-Pacific region.
Key players and market strategies:
There are several key growth strategies that companies operating in the critical limb ischemia treatment market are adopting in order to stay competitive and maintain market growth.
One of the main strategies is the development and launch of new and innovative treatments for critical limb ischemia. This includes the development of new medications, such as angiogenesis drugs and anti-platelet drugs, as well as the development of new surgical devices, such as drug-eluting stents and drug-coated balloons.
Another key growth strategy is the expansion of geographical reach through partnerships, collaborations, and acquisitions. Companies are seeking to expand into new markets and increase their presence in existing markets through partnerships with local healthcare providers and distributors.
Additionally, companies are seeking to enter new markets through mergers and acquisitions, which can help them gain access to new customers, products, and technologies.
Some of the biggest companies operating in the global critical limb ischemia treatment market are Abbott Laboratories, Boston Scientific Corporation, Cesca Therapeutics Inc., Cardiovascular Systems, Inc., Pluristem Therapeutics Inc., Micro Medical Solutions, LimFlow SA, Rexgenero Ltd., and many more.
Market Segmentation:
By Treatment
- Medication
- Antihypertensive Agents
- Antiplatelet Drugs
- Antithrombotic Agents
- Lipid-lowering Agents
- Others
- Surgery
- Embolic Protection Devices
- Peripheral Dilatation System
- Balloon Dilators
- Vascular Stents
By End-user
- Hospitals
- Clinics
- Ambulatory surgical centers
By Region
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Brazil
- Rest of South America
- Introduction
- Research Objectives
- Report Assumptions
- Research Methodology
- Abbreviations
- Preface
- Market Definition
- Report Scope and Market Segmentation
- Research Highlights
- Market Synopsis: Global Critical Limb Ischemia Treatment Market
- Global Critical Limb Ischemia Treatment Market Qualitative Analysis
- Trends
- Market trends
- Technology Trends
- PESTLE Analysis (For 3 prominent countries)
- Market Influencers
- Driving Forces
- Hindering Forces
- Opportunities
- COVID-19 impact
- Porter’s Five Forces Analysis
- Value Chain Analysis
- Trends
- Global Critical Limb Ischemia Treatment Market Analysis and Forecast, by Treatment
- Overview and definitions
- Key segment analysis
- Global Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Treatment, 2019 – 2032
- Medication
- Antihypertensive Agents
- Antiplatelet Drugs
- Antithrombotic Agents
- Lipid-lowering Agents
- Others
- Surgery
- Embolic Protection Devices
- Peripheral Dilatation System
- Balloon Dilators
- Vascular Stents
- Medication
- Global Critical Limb Ischemia Treatment Market Analysis and Forecast, by End Use
- Overview and definitions
- Key segment analysis
- Global Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospitals
- Clinics
- Ambulatory surgical centers
- Global Critical Limb Ischemia Treatment Market Analysis and Forecast, by Region
- Overview and definitions
- Key segment analysis
- Global Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Region, 2019 – 2032
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- South America
- North America Critical Limb Ischemia Treatment Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- North America Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Treatment, 2019 – 2032
- Medication
- Antihypertensive Agents
- Antiplatelet Drugs
- Antithrombotic Agents
- Lipid-lowering Agents
- Others
- Surgery
- Embolic Protection Devices
- Peripheral Dilatation System
- Balloon Dilators
- Vascular Stents
- North America Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospitals
- Clinics
- Ambulatory surgical centers
- North America Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Country, 2019 – 2032
- United States
- Canada
- Rest of North America
- Medication
- Europe Critical Limb Ischemia Treatment Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- Europe Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Treatment, 2019 – 2032
- Medication
- Antihypertensive Agents
- Antiplatelet Drugs
- Antithrombotic Agents
- Lipid-lowering Agents
- Others
- Surgery
- Embolic Protection Devices
- Peripheral Dilatation System
- Balloon Dilators
- Vascular Stents
- Europe Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospitals
- Clinics
- Ambulatory surgical centers
- Europe Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Country, 2019 – 2032
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Medication
- Asia Pacific Critical Limb Ischemia Treatment Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- Asia Pacific Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Treatment, 2019 – 2032
- Medication
- Antihypertensive Agents
- Antiplatelet Drugs
- Antithrombotic Agents
- Lipid-lowering Agents
- Others
- Surgery
- Embolic Protection Devices
- Peripheral Dilatation System
- Balloon Dilators
- Vascular Stents
- Asia Pacific Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospitals
- Clinics
- Ambulatory surgical centers
- Asia Pacific Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Country, 2019 – 2032
- China
- Japan
- South Korea
- India
- Australia
- Rest of Asia Pacific
- Medication
- Middle East & Africa Critical Limb Ischemia Treatment Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- Middle East & Africa Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Treatment, 2019 – 2032
- Medication
- Antihypertensive Agents
- Antiplatelet Drugs
- Antithrombotic Agents
- Lipid-lowering Agents
- Others
- Surgery
- Embolic Protection Devices
- Peripheral Dilatation System
- Balloon Dilators
- Vascular Stents
- Middle East & Africa Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospitals
- Clinics
- Ambulatory surgical centers
- Middle East & Africa Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Country, 2019 – 2032
- UAE
- Saudi Arabia
- South Africa
- Rest of MEA
- Medication
- South America Critical Limb Ischemia Treatment Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- South America Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Treatment, 2019 – 2032
- Medication
- Antihypertensive Agents
- Antiplatelet Drugs
- Antithrombotic Agents
- Lipid-lowering Agents
- Others
- Surgery
- Embolic Protection Devices
- Peripheral Dilatation System
- Balloon Dilators
- Vascular Stents
- South America Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospitals
- Clinics
- Ambulatory surgical centers
- South America Critical Limb Ischemia Treatment Market Estimates (US$ Mn), by Country, 2019 – 2032
- Brazil
- Argentina
- Rest of South America
- Medication
- Competition Analysis – Global Critical Limb Ischemia Treatment Market
- Market Composition
- Market Share Analysis (%), by Supplier (2022)
- Company Profiles
- Abbott Laboratories
- Business overview
- Geographic presence
- Product portfolio
- Financial facts
- Relevant news and strategic view
- Boston Scientific Corporation
- Cesca Therapeutics Inc.
- Cardiovascular Systems, Inc.
- Pluristem Therapeutics Inc.
- Micro Medical Solutions
- LimFlow SA
- Rexgenero Ltd.
- Abbott Laboratories
- Conclusion & Recommendations
Frequently asked questions about this report
What is the Compound Annual Growth Rate (CAGR) of the critical limb ischemia treatment market?
The critical limb ischemia treatment market is estimated to exhibit a CAGR of 7.8% from 2023 to 2032.
How big is the CLI treatment market?
The critical limb ischemia treatment market was estimated to be US$ 4.57 Billion in 2022.
Why ambulatory surgery center is the fastest-growing segment in the CLI treatment market?
The ambulatory surgical center is the fastest-growing end-user due to its convenience and accessibility.
What are the factors driving the critical limb ischemia treatment market?
The critical limb ischemia treatment market is driven by several factors, including the increasing incidence of PAD and CLI, the rising geriatric population, growing awareness of CLI and available treatments, and the growing prevalence of lifestyle diseases such as diabetes and obesity.
What are the prominent critical limb ischemia treatment market players across the globe?
Some of the prominent players operating in the critical limb ischemia treatment market are Abbott Laboratories, Boston Scientific Corporation, Cesca Therapeutics Inc., Cardiovascular Systems, Inc., Pluristem Therapeutics Inc., Micro Medical Solutions, LimFlow SA, Rexgenero Ltd., and many more.
How is the regional performance of the market?
The fastest-growing segment of the global critical limb ischemia treatment market is the Asia-Pacific region, particularly in countries such as China, India, and Japan. This is due to the increasing incidence of critical limb ischemia and rising geriatric population.
Which treatment type is the largest in the critical limb ischemia treatment market?
The surgical segment is the largest segment of the critical limb ischemia treatment market. This is due to the fact that in many cases, CLI requires surgical intervention to restore blood flow to the affected limb, particularly in cases of advanced disease or tissue loss.